More Opthea Limited news
Opthea LimitedASX: OPT

Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME

Jun 9, 2020 at 11:08 PM EDT · Issued by Opthea Limited

Filed with ASX · Jun 9, 2020 at 11:08 PM EDT · 5 pages · English and French

On 6ix: 6ix.com/news/opthea-reports-positive-ph2a-trial-results-of-opt-302-in-dme

Opthea Limited on 6ix

Story so far

  • Opthea Completes Patient Dosing in Phase 2a DME TrialMar 30, 2020
  • Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DMEJan 7, 2020
  • Opthea Completes Final Patient Visit in Phase 2b wAMD TrialMay 15, 2019

Earlier from Opthea

  • Opthea Completes Patient Dosing in Phase 2a DME TrialMar 29, 2020
  • Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DMEJan 6, 2020
  • Opthea Equity Raising PresentationDec 1, 2019
  • Opthea Presentation for Ophthalmology Innovation SummitOct 10, 2019
  • Opthea Receives A$14.6m R&D Tax IncentiveSep 30, 2019

Later from Opthea

  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)Jul 26, 2020
  • Opthea Completes Successful FDA and EMA Meetings for Phase 3Aug 20, 2020
  • Opthea Announces Plans for Potential US listing and IPOAug 23, 2020
  • Opthea Full Year Financial Report 2020Aug 27, 2020
All Opthea news releases↗

Follow Opthea into a list and get an email when it puts out news.

Follow Opthea
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer